Wedbush Reiterates “Outperform” Rating for Aprea Therapeutics (NASDAQ:APRE)

Aprea Therapeutics (NASDAQ:APREGet Free Report)‘s stock had its “outperform” rating reiterated by analysts at Wedbush in a note issued to investors on Thursday,RTT News reports. They currently have a $11.00 price objective on the stock.

Aprea Therapeutics Trading Down 4.4%

Shares of NASDAQ APRE opened at $1.68 on Thursday. Aprea Therapeutics has a 12 month low of $1.41 and a 12 month high of $5.01. The firm has a market capitalization of $9.26 million, a PE ratio of -0.71 and a beta of 1.22. The firm has a fifty day simple moving average of $1.72 and a two-hundred day simple moving average of $2.51.

Aprea Therapeutics (NASDAQ:APREGet Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.01). Aprea Therapeutics had a negative return on equity of 68.39% and a negative net margin of 1,095.02%. The company had revenue of $0.16 million during the quarter. On average, sell-side analysts predict that Aprea Therapeutics will post -2.55 earnings per share for the current year.

Hedge Funds Weigh In On Aprea Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets bought a new position in shares of Aprea Therapeutics in the 4th quarter worth about $43,000. LPL Financial LLC bought a new position in shares of Aprea Therapeutics during the fourth quarter valued at approximately $53,000. Landscape Capital Management L.L.C. bought a new position in Aprea Therapeutics during the 4th quarter valued at approximately $116,000. Finally, Stonepine Capital Management LLC increased its position in Aprea Therapeutics by 8.8% during the 4th quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock valued at $491,000 after buying an additional 12,047 shares in the last quarter. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

(Get Free Report)

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.

Featured Stories

Receive News & Ratings for Aprea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aprea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.